Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.

Abstract: The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-Met tyrosine kinase activity.

Abstract: Disclosed herein are a new N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidin-2,4-diamine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical composition for the prevention or treatment of cancers containing the same as an active ingredient. The compound of the present invention has excellent inhibitory effects against the activities of anaplastic lymphoma kinase (ALK) and activated cdc42-associated kinase (ACK1) and thus can improve the therapeutic effects on the treatment of cancer cells having anaplastic lymphoma kinase fusion proteins such as EML4-ALK and NPM-ALK, and also effectively prevent the recurrence of cancers thus being useful as a pharmaceutical composition for the prevention and treatment of cancers.

Abstract: The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-Met tyrosine kinase activity.

Abstract: Disclosed herein are a new N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidin-2,4-diamine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical composition for the prevention or treatment of cancers containing the same as an active ingredient. The compound of the present invention has excellent inhibitory effects against the activities of anaplastic lymphoma kinase (ALK) and activated cdc42-associated kinase (ACK1) and thus can improve the therapeutic effects on the treatment of cancer cells having anaplastic lymphoma kinase fusion proteins such as EML4-ALK and NPM-ALK, and also effectively prevent the recurrence of cancers thus being useful as a pharmaceutical composition for the prevention and treatment of cancers.

Abstract: Provided is a tag attached to a mobile unit to estimate a position of the mobile unit, which can minimize the estimation position error of a mobile unit even while increasing the positioning interval of a beacon, and the tag includes a radio frequency (RF) transceiver transmitting and receiving an RF signal, an ultrasonic receiver receiving an ultrasonic signal, and a controller transmitting the RF signal to a beacon through the RF transceiver, receiving an RF response signal to the RF signal to calculate a distance between the mobile unit and the beacon based on the RF signal, and calculating a distance between the mobile unit and the beacon based on the ultrasonic signal when the ultrasonic signal, which is transmitted from the beacon together with the RF response signal, is received through the ultrasonic receiver.

Abstract: The present invention relates to benzopyran derivatives substituted with secondary amines including imidazole, their preparation, and pharmaceutical compositions containing them. The present invention is pharmacologically useful for the treatment of cancer, rheumatoid arthritis, and diabetic retinopathies through anti-angiogenic properties, and also pharmacologically useful in the protection of heart and neuronal cells against ischemia-reperfusion injury or preserving organs.

Abstract: The present invention relates to 1-/2-substituted-1H/-2H-[1,2,3]triazolo[4,5-g]phthalazine-4,9-dione compounds and their pharmaceutically acceptable salts, a process for preparing the compounds and a pharmaceutical composition comprising the compounds. The compounds are shown to effectively inhibit cell proliferation and are thus expected to be used for treatment or prevention or treatment of various cancers or as an ancillary(auxiliary) means of the same.

Abstract: A pharmaceutical composition comprising a lower alcohol-soluble extract of Ferula asafoedida L or a compound isolated therefrom including galbanic acid, karatavicinol, umbelliprenin, farnesiferol B, or farnesiferol C exhibits a potent anticancer activity.

Abstract: A directly accessing apparatus and method of a disk recording and reproducing system, in which scene changes are detected and the very next specific images in the start portions of continuous images after the scene changes are captured, decimated and stored in a temporary storage unit, and the output of the temporary storage unit is edited and recorded on a specific recording area of a disk after a corresponding moving image is entirely recorded on the disk. Accordingly, corresponding moving images can be visually indexed so as to be directly accessed.

Abstract: A two-stage fluidized bed reducing apparatus and a reducing method for fine iron ore of a wide particle size distribution with an increased degree of utilization of the reducing gas. Fine iron particles dropping through the holes of a gas distributor can be recycled into the fluidized bed furnace, thereby preventing an impediment of the reducing gas flow due to abnormal defluidizing or channeling. A first fluidized bed furnace dries, pre-heats and pre-reduces the fine iron ore, and a second fluidized bed furnace finally reduces the pre-reduced iron ore. Downstream of the respective fluidized beds are installed intermediate hoppers and gas/solid sealing valves. Thus, the fine iron ore particles which drop through the holes of gas distributors during the abnormal operation are recycled to the furnaces. Accordingly, the gas flow is not impeded.

Abstract: A fluidized bed reduction reactor has a plurality of fluidized bed reactors (10) with inner gas distributors (19). A charge duct (12) passes through the top of the fluidized bed reactor (10) with a free end to charge a fine iron ore into said reactor (10). The free end of the iron ore charging duct (12) is positioned close to the top center of the gas distributor (19). A spiral-shaped partition weir (13) is placed over the gas distributor and surrounds the iron ore charging duct (12) while being spirally extended to an inner wall of the fluidized bed reactor (10) where it is fixed. The fine iron ore is fluidized and reduced while spirally flowing from the center of the fluidized bed reactor (10) to its inner wall. In this structure, the back mixture phenomenon where the reacted fine iron ore is mixed with the non-reacted fine iron ore does not occur.

Abstract: In the process for the production of liquid pig iron 943) or liquid steel pre-products from charging substances comprising iron ore (5) and fluxes and at least partially containing a portion of fines, the iron ore is directly reduced to sponge iron in at least two reduction stages (1, 2) by the fluidized bed method, the sponge iron is melted in a melt-down gasifying zone (39) under the supply of carbon carriers and an oxygen-containing gas, and a CO- and H2-containing reducing gas is produced which is injected into reduction zones of the reduction stages (1, 2), is reacted there, is withdrawn as a top gas and optionally is supplied to a consumer.

Abstract: In the process for the production of liquid pig iron 943) or liquid steel pre-products from charging substances comprising iron ore (5) and fluxes and at least partially containing a portion of fines, the iron ore is directly reduced to sponge iron in at least two reduction stages (1, 2) by the fluidized bed method, the sponge iron is melted in a melt-down gasifying zone (39) under the supply of carbon carriers and an oxygen-containing gas, and a CO- and H2-containing reducing gas is produced which is injected into reduction zones of the reduction stages (1, 2), is reacted there, is withdrawn as a top gas and optionally is supplied to a consumer.

Abstract: In a method for treating particulate material in the fluidized bed method, the particulate material is maintained in a fluidized bed by a treating gas flowing from bottom to top and thereby is treated. To minimize the consumption of treating gas and to reduce entrainment of fine particles by the treating gas, a particulate material having a wide grain distribution and a relatively high portion of fines is used for treatment and the treating gas in the fluidized bed is maintained at a superficial velocity less than the velocity required for fluidizing the largest particles of said particulate material.

Abstract: A fluidized bed reducing system for reducing a fine iron ore is disclosed, in which the structure of the fluidized bed reducing furnace is improved such that the coarse iron ore particles are distributed in the lower portion of the fluidized bed within the furnace and the fine iron ore particles are distributed in the upper portion of the fluidized bed. Thus, the average residence times of the particles in the furnace are adjusted differently for different ore sizes, so that the reducing efficiency can be improved, and that the residence time of the reducing gas in the furnace can be extended, thereby improving the degree of gas utilization.

Abstract: The present invention relates to a platinum complex conjugated to a cyclotriphosphazene represented by Formula 1 and a preparation method thereof. The platinum complex according to the present invention can be used as an anticancer agent.

Abstract: A smelting reduction apparatus and a method for producing molten pig iron using the smelting reduction apparatus are disclosed. The molten pig iron is produced by using iron ore, sintered ore or iron pellets, so that the reduced iron discharge operation from a pre-reducing furnace to a melter-gasifier would not give any influence to the operation of the pre-reducing furnace. An iron ore is pre-reduced at a pre-reducing furnace by utilizing a reducing off-gas which is produced from a melter-gasifier. The pre-reduced iron ore is melted and reduced at the melter-gasifier. The reducing gas which is discharged from the melter-gasifier is supplied through an ascending duct and a cyclone into the pre-reducing furnace. The fine iron ore which is collected at the cyclone is spouted through a recycling device and a melter-burner into the melter-gasifier.